Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Organisation › Details

Pharmalink AB

Pharmalink is a Swedish specialty pharma company developing high value products for niche indications. Pharmalink draws on its extensive experience of pharmaceutical development and marketing and the excellence of medical science in Sweden to identify and progress products that address significant unmet medical needs. With a successful history in pharmaceutical sales and marketing, and highly experienced, dynamic management team, Pharmalink is currently focused on the development of valuable, de-risked projects using a repurposing and reformulation strategy. It has two late-stage clinical phase products under development, Nefecon® and Busulipo™, having successfully divested its Xepol® product in 2010. Pharmalink is actively seeking opportunities to acquire or in-licence product opportunities in niche and hospital care indications. *

 

Period Start 2012-01-04 existent
Period End 2017-11-15 renamed
  Group Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)
  Today Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)
  Successor Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)
Products Industry pharmaceutical
  Industry 2 Nefecon®
Persons Person Aguiar-Lucander, Renée (Pharmalink AB 201708 CEO)
  Person 2 Johansson, Fredrik (Pharmalink AB 201708– CFO before Birdstep Technology/Techstep ASA)
     
Region Region Stockholm
  Country Sweden
  Street 26B Wallingatan
  City 111 24 Stockholm
  Tel +46-8-411-3005
    Address record changed: 2018-07-24
     
Basic data Employees n. a.
     
    * Document for �About Section�: Pharmalink AB. (10/29/12). "Press Release: Pharmalink AB Strengthens Senior Management Team. Dr. Heather Cook Appointed Director of Regulatory Affairs and Marek Poszepczynski as Director of Business Development". Stockholm.
     
   
Record changed: 2017-11-25

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top